Biotechnology

Cellution Biologics' acquisition of SimpliDerm is more than a simple expansion. It's a tale of two diverging strategies in the high-stakes biologics market.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

An award-winning platform is bringing scientific scrutiny to the supplement aisle. Can this push for transparency force a new standard of accountability?

New biotech Rinascera launches with a veteran team and a clinical-stage pipeline. Is its disciplined, asset-acquisition strategy the future for rare diseases?

As OmniAb preps its Q2 results, the real story isn't just the numbers. It's the 'Biological Intelligence' platform reshaping drug discovery from the ground up.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

A new biotech collaboration aims to accelerate a novel diagnostic platform, highlighting a growing trend of outsourcing operations to speed innovation in precision medicine.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

South Korea's HIGHER Corp. unveils preclinical data for HILO WAVE®, a dual-hyaluronic acid booster that may bypass the inflammatory pathways of competitors.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

A new deal between biosolutions giant Novonesis and innovator TurtleTree aims to mass-produce a vital milk protein, signaling a tectonic shift for the nutrition industry.

Parse Biosciences, QIAGEN's strategic acquisition, just partnered with Australia's Garvan Institute. It's more than science—it's a calculated play to win.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

With a strategic investment from Persephoni, SelSym Biotech is advancing SymClot, a synthetic blood-clotting agent that could redefine emergency medicine.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

With a Parkinson's therapy in hand and a universal AI model, Cellular Intelligence adds seasoned leaders to turn biological ambition into durable value.

As Corrixr's novel CRISPR therapy nears human trials, the appointment of Seagen veteran Nancy Whiting signals a strategic shift from lab to market.